In my opinion, Celgene Corp (CELG) may simply be the most compelling biotech company in the world. With the stock down near $100 from $140 less than a year ago, now may be the time to add this biotech marvel to your shopping list.
Recent News
Celgene’s largest drug is Revlimid and while it has been one of the greatest successes ever in biotechnology, it faced a patent lawsuit and decision that hung over the stock. News came out in late December that an agreement had been reached where Celgene would allow for generic brands to sell starting in 2026.
While that’s a full year before the patent expires, we now can now rest assured that Revlimid will have more than another decade to grow and sell without competition. The stock rose 10% on the day when that news was released.
Â
Pipeline
Before we get into the details of what does exist, let’s look at the incredible pipeline for Celgene relative to all of biotechnology in the United States. In the image below, we have plotted the number of Phase III trials on the y-axis and ranked the largest biotechs on the x-axis.
That’s right, Celgene has more products in Phase III than any other biotech, save for Amgen (AMGN), where it’s tied.
Now we can do the same thing with Phase II trials.
Celgene has the most Phase II trials and Phase III trials.
Current Products
In the last year, CELG has generated over $9.2 billion in revenue. Here’s a chart of Celgene’s revenue (TTM) over the last sixteen years.
    continue reading on the next page…
